On June 16, the official website of the Drug Clinical Trial Registration and Information Disclosure Platform showed that Qilu Pharmaceutical has initiated an open-label, multicenter Phase I clinical study (Registration No.: CTR20262372) to evaluate the safety, tolerability, pharmacokinetics, and preliminary…
On June 15, the Drug Clinical Trial Registration and Information Disclosure Platform showed that The United Laboratories (TUL) has registered a Phase III clinical trial (overweight/obesity) for UBT251 Injection. This is a randomized, double-blind, parallel, placebo-controlled Phase III study designed…
On June 11, the U.S. clinical trials registry website showed that Biohaven has initiated the first Phase III clinical trial (BHV1400-301) for BHV-1400, its next-generation degrader. The study is a randomized, multicenter, double-blind, placebo-controlled clinical trial (n=420) designed to evaluate…
On May 26, 2026, Henlius (2696.HK) announced that the first patient has been dosed in China in the randomized, double-blind, multicenter, parallel-controlled Phase II/III clinical study evaluating pimurutamab (HLX07), the Company’s proprietary recombinant anti-EGFR monoclonal antibody, in combination with H药 汉斯状®…
On June 4 local time, the ClinicalTrials website showed that Hengrui Medicine registered a Phase III clinical trial of HRS-7535 for the treatment of chronic kidney disease (CKD) . This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group Phase III study designed…
Roche’s Obinutuzumab Injection (Brand Name: Gazyvaro®/Gazyva®) has been granted priority review by the CDE for the treatment of primary membranous nephropathy (pMN). In February of this year, Roche announced that the study met its primary endpoint: the proportion of patients…
On June 4 local time, the ClinicalTrials website showed that SystImmune, a wholly-owned subsidiary of Baili Tianheng, registered a Phase III clinical trial of BL-M14D1 in combination with Tecentriq for the first-line treatment of extensive-stage small cell lung cancer. According…
This morning, Qihan Biotech reported preliminary positive clinical data for its in vivo CAR-T therapy. Qihan Biotech did not disclose specific information about its in vivo CAR-T pipeline. It is only known that the company’s first in vivo CAR-T program…
On May 20, CDE issues an announcement that Insilico Medicine’s new drug clinical trial application for ISM8969/HT-001 tablets has been accepted for review. The drug received an FDA clinical trial approval in January this year. The acceptance of the domestic…
On May 20, the official website of the Drug Clinical Trial Registration and Information Disclosure Platform announced the formal registration of a Phase I clinical study. The study aims to evaluate the safety, tolerability, and pharmacokinetic profile of IBI3031 following…